High-Level of Notch 1/Jagged 1 Level up Regulated Chemo-Resistance of Cisplatin in NSCLC
Nasser Ghaly Yousifa, Alla Mohammed Sadiqueb, Laith Mohammad Abbas Al-Huseinic, Muntadher NoamanJassimd, Najah R. Hadie, Fadhil Al-Amranf
Lung cancer is the top ranked cause of cancer death worldwide and lung cancer alone. Platinum-based chemotherapy increase survival rates and improves the life quality in patients, and many suggested pathways of the efficacy of cisplatin in treatment of NSCLC. This study aimed to identify the signaling pathway of Notch 1/ Jagged 1 in mechanistic action of cisplatin treatment of NCSLC. Fifty patients having NSCLC were enrolled in this study include 37 patient’s male while females were 13 patients, with a median age of 42.5 years (range, from 33 to 76 years). Clinical factors such as sex, age, tumor site, size and grade, metastasis, and T.N.M. stage, were collected. Immunohistochemistry including the use of the method of avidinbiotin peroxidase on all tissues, while patient blood sample use for total RNA and reverse transcribed and Kaplan-Meier method used for plotted the survival curves.
The degree of Notch 1/Jagged1 protein-expression were mainly more in patient include male more than the female (P<0.05). It’s clear; the expression levels of Notch1 proteins were in relation with grades of tumor and its pathological state. The expression levels of Notch 1/Jagged1 were strongly related (high or low) in patients not respond to chemotherapy and tumor progress or metastasis disease to lung or brain. The survival rate of patients with low expression Notch 1/Jagged 1 whom treated with cisplatin-based chemotherapy was 100% during 8-months of follow up. High Notch-1/Jagged-1 levels expression invert a poor prognosis of NSCLC patients and may represent a new strategy to decrease resistance of cisplatin based treated NSCLC patients.